Recent advances in the immunology of chronic rejection

Current Opinion in Nephrology and Hypertension

Volumn 11, Issue 3, 2002, Pages 315-321

  Allan, James S ^a   Madsen, Joren C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTING CELL; CHRONIC DISEASE; GRAFT REJECTION; HISTOLOGY; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RAT; REVIEW; T LYMPHOCYTE; IMMUNOLOGY; PATHOLOGY; RISK FACTOR;

CHRONIC DISEASE; GRAFT REJECTION; HUMANS; RISK FACTORS;

EID: 0036247464     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200205000-00008     Document Type: Review

References (66)

1. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth official report - 2001
2. The UNOS scientific renal transplant registry - 2000
3. Chronic liver allograft rejection: A National Institute of Diabetes and Digestive and Kidney Diseases interinstitutional study analyzing the reliability of current criteria and proposal of an expanded definition
4. Intertubular capillary changes in the cortex and medulla of transplanted kidneys and their relationship with transplant glomerulopathy: An ultrastructural study of 12 transplantectomies
5. Both alloantigen-dependent and -independent factors influence chronic allograft rejection
6. Immune mechanisms of cardiac allograft vasculopathy: An update
7. Coronary atherosclerosis in transplanted mouse hearts: I. Time course and immunogenetic and immunopathological considerations
8. Diagnosis and management of bronchiolitis obliterans
9. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group
10. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts
11. Imaging of lung transplantation
12. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy
13. Cardiac transplantation in the rat: II. Alterations of the severity of donor graft arteriosclerosis by modulation of the host immune response
14. HLA compatibility and organ transplant survival
15. The influence of conventional and cross-reactive group HLA matching on cardiac transplant outcome: An analysis from the United Network of Organ Sharing Scientific Registry
16. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations
17. Risk factors for the development of obliterative bronchiolitis after lung transplantation
18. Development of obliterative bronchiolitis after allogeneic rat lung transplantation: Implication of acute rejection and the time point of treatment
19. Prolonged blockade of CD40-CD40 ligand interactions by gene transfer of CD401g results in long-term heart allograft survival and donor-specific hyporesponsiveness, but does not prevent chronic rejection
20. The impact of ischemia/reperfusion injury on specific and non-specific early and late chronic events after organ transplantation
21. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury
22. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney: Inhibition by a soluble P-selectin ligand
23. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury
24. Effects of brain death on donor organ viability
25. Accelerated rejection of renal allografts from brain-dead donors
26. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction
27. Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on highsodium diet
28. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: Potential implications in transplant arteriopathy
29. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: A means for graft rejection and immunosuppression
30. Role of alloimmunity in clinical transplantation
31. Strain specific effects of cytomegalovirus on endothelial cells: Implications for investigating the relationship between CMV and cardiac allograft vasculopathy
32. Viral infections and their impact on chronic renal allograft dysfunction
33. Association of viral genome with graft loss in children after cardiac transplantation
34. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells
35. Replacement of graft-resident donor-type antigen presenting cells alters the tempo and pathogenesis of murine cardiac allograft rejection
36. The role of 'indirect' recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice
37. Direct and indirect antigen recognition: The pathways to allograft immune rejection
38. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides
39. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy
40. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction
41. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients
42. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy
43. The UNOS scientific renal transplant registry - Ten years of kidney transplants
44. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome
45. Indirect recognition and antibody production against a single mismatched hla-A2-transgenic molecule precede the development of obliterative airway disease in murine heterotopic tracheal allografts 1
46. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
47. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model
48. Mixed hematopoietic chimerism induces long-term tolerance to cardiac allografts in miniature swine
49. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys
50. Costimulatory blockade for induction of mixed chimerism and renal allograft tolerance in nonhuman primates
51. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection
52. The role of T cell apoptosis in transplantation tolerance
53. The in vivo mechanism of action of CTLA4lg
54. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4
55. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
56. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
57. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression
58. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
59. CTLA4lg-induced linked regulation of allogeneic T cell responses
60. CD28-BT-mediated T cell costimulation in chronic cardiac allograft rejection: Differential role of B7-1 in initiation versus progression of graft arteriosclerosis
61. Regulatory functions of self-restricted MHC class II allopeptide- specific Th2 clones in vivo
62. Allochimeric class I MHC molecules prevent chronic rejection and attenuate alloantibody responses
63. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
64. Transplant coronary artery disease: A novel model independent of cellular alloimmune response
65. Immunologic ignorance of organ allografts
66. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity